Clinical Trial

An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) parameters of the combination of APG777 + APG990 in adults with moderate-to-severe atopic dermatitis (AD), in comparison to dupilumab. The duration of the study will be approximately 82 weeks for each participant and will consist of a Screening Period (up to 6 weeks), Treatment Period (Baseline-Week 24), and Follow-up Period (Week 28-Week 76).
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2025-06-11; most recent amendment 2026-06-05.
Status change: Recruiting → Active, Not Recruiting 2026-03-23
Trial Details
NCT Number NCT07027527
Lead Sponsor Apogee Therapeutics, Inc.
Conditions Atopic Dermatitis
Enrollment 86 participants
Start Date 2025-06-04
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-06-08